Zydus Cadila seeks approval for its repurpose Hepatitis C drug for Covid-19
India's Cadila
Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim
results from a late-stage trial, the drug maker said on Monday.
A single
dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the
advanced stages of the disease, Cadila said in a statement to stock exchanges.
About 91%
of patients treated with the drug tested negative for COVID-19 in standard
RT-PCR tests by day seven, compared to nearly 79% who were given the standard
of care, the company said citing Phase-III clinical trial data.
The drug,
known as Pegylated Interferon alpha-2b and branded as 'PegiHep' by Cadila, was
originally approved for liver disease Hepatitis C and launched in India 10
years ago. It is being repurposed to treat COVID-19. Read More
Comments
Post a Comment